Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes

Epidemiology and Infection

Volumn 136, Issue 5, 2008, Pages 670-678

  Weyer, J ^a,c   Kuzmin, I V ^b   Rupprecht, C E ^b   Nel, L H ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; MOKOLA VIRUS GLYCOPROTEIN; RABIES VIRUS GLYCOPROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS PROTEIN; VIRUS VECTOR; WEST CAUCASIAN BAT VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; FEMALE; GENE THERAPY; IMMUNE RESPONSE; LAGOS BAT LYSSAVIRUS; MOKOLA VIRUS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RABIES; RABIES VIRUS; VACCINATION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN; WEST CAUCASIAN BAT VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; FEMALE; LYSSAVIRUS; MICE; NEUTRALIZATION TESTS; RABIES; RABIES VACCINES; VACCINIA VIRUS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 41549123670     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268807008965     Document Type: Article

References (42)

1. Tordo N, et al. Lyssaviruses. In: Fauquet CM, et al. eds. Virus taxonomy: The classification and nomenclature of viruses. The 8th Report of the International Committee on Taxonomy of Viruses. San Diego: Oxford Academic, 2006, pp. 623-629.
2. WHO. World Health Organization Expert Consultation on Rabies, 5-8 October 2004, First report. World Health Organization Technical report series 931. Geneva: World Health Organization, 2005, pp. 15-19. 105.
3. Arai YY, et al. New lyssavirus genotype from lesser mouse-eared bats (Myotis blythi), Kyrghyzstan. Emerging Infectious Disease 2003; 9: 333-337.
4. Botvinkin AD, et al. Novel lyssaviruses isolated from bats in Russia. Emerging Infectious Disease 2003; 9: 1623-1625.
5. Kuzmin IV, et al. Bat lyssaviruses (Aravan and Khujand) from Central Asia: Phylogenetic relationships according to N, P and G gene sequences. Virus Research 2003; 97: 65-79.
6. Kuzmin IV, et al. Phylogenetic relationships of Irkut and West Caucasian bat viruses within the Lyssavirus genus and suggested quantitative criteria based on the N gene sequence for lyssavirus genotype definition. Virus Research 2005; 111: 28-43.
7. Badrane H, et al. Evidence for two lyssavirus phylo-groups with distinct pathogenicity and immunogenicity. Journal of Virology 2001; 75: 3268-3276.
8. Hanlon CA, et al. Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Research 2005; 111: 44-54.
9. Nel LH. Vaccines for lyssaviruses other than rabies. Expert Reviews of Vaccines 2005; 4: 553-540.
10. Paweska JT, et al. Fatal human infection with rabies-related Duvenhage virus, South Africa. Emerging Infectious Disease 2006; 12: 1965-1967.
11. Nel LH, et al. A comparison of DNA vaccines for the rabies-related virus, Mokola. Vaccine 2003; 21: 2598-2606.
12. Weyer J. Immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes [Thesis]. Pretoria, South Africa: University of Pretoria, 2006, pp. 127-156.
13. Beuken E, Vink C, Bruggeman CA. One step procedure for screening recombinant plasmids by size. BioTechniques 1998; 24: 748-750.
14. Earl PL, et al. Preparation of cell cultures and vaccinia virus stocks. In: Current Protocols in Molecular Biology. Indianapolis, IN: John Wiley and Sons, 1998, pp. 16.16.1-16.20.2.
15. Byrd CM, Hruby DE. Construction of recombinant vaccinia virus. Cloning into the thymidine kinase locus. In: Isaacs SN, ed. Vaccinia virus and poxvirology. Methods and Protocols. Totowa, NJ: Humana Press, 2005, pp. 31-39.
16. Pasamontes L, et al. Direct identification of recombinant virus plaques by PCR. Journal of Virological Methods 1991; 35 137-141.
17. Esposito J, Condit R, Objeski J. The preparation of orthopoxvirus DNA. Journal of Virological Methods 1981; 2: 175-179.
18. Dean DJ, Abelseth MK, Atanasiu P. The fluorescent antibody test. In: Meslin F-X, Kaplan MM, Koprowski H, eds. Laboratory Techniques in Rabies, 4th edn. Geneva: World Health Organization, 1996, pp. 88-95.
19. Smith JS, Yager PA, Baer GM. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody. In: Meslin F-X, Kaplan MM, Koprowski H, eds. Laboratory Techniques in Rabies, 4th edn. Geneva: World Health Organization, 1996, pp. 181-192.
20. Markotter W, et al. Lagos Bat virus, South Africa. Emerging Infectious Diseases 2006; 12: 504-506.
21. Nel L, et al. New cases of Mokola virus infection in South Africa: A genotypic comparison of Southern African virus isolates. Virus Genes 2000; 20: 103-106.
22. Familusi JB, Moore DL. Isolation of a rabies-related virus from the cerebrospinal fluid of a child with aseptic meningitis. African Journal of Medical Science 1972; 3: 93-96.
23. Familusi JB, et al. A fatal human infection with Mokola virus. American Journal of Tropical Medicine and Hygiene 1972; 21: 959-963.
24. Boulger IR, Porterfield JS. Isolation of a virus from Nigerian fruit bats. Transcripts of the Royal Society of Tropical Medicine and Hygiene 1958; 52: 421-424.
25. Sureau P, Tignor GH, Smith AL. Antigenic characterization of the Bangui strain (ANCB-672d) of Lagos bat. Annals of Virology 1980; 131: 25-32.
26. Mebatsion T, Cox JH, Frost JW. Isolation and characterization of 115 street rabies virus isolates from Ethiopia by using monoclonal antibodies: Identification of 2 isolates as Mokola and Lagos bat viruses. Journal of Infectious Diseases 1992; 166: 972-977.
27. Fooks AR. The challenge of emerging lyssaviruses. Expert Review of Vaccines 2004; 3: 89-92.
28. Badrane H, Tordo N. Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. Journal of Virology 2001; 75: 8096-8104.
29. Markotter W, et al. Isolation of Lagos bat virus from water mongoose. Emerging Infectious Diseases 2006; 12: 1913-1918.
30. Kieny M-P, et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984; 312: 163-166.
31. Rupprecht CE, Kieny M-P. Development of a vaccinia-rabies glycoprotein recombinant virus vaccine. In: Campbell JB, Charlton KM, eds. Rabies. Boston, USA: Kluwer Academic Publishers, 1988, pp. 335-364.
32. Tordo N, et al. Structure and expression in baculovirus of the mokola virus glycoprotein: An efficient recombinant vaccine. Virology 1993; 194: 59-69.
33. Bahloul C, et al. DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 1998; 16: 417-425.
34. Jallet C, et al. Chimeric lyssavirus glycoprotein genes with increased immunological potential. Journal of Virology 1999; 73 225-233.
35. Bourhy H, Kiss B, Tordo N. Molecular diversity of the lyssavirus genus. Virology 1993; 194: 70-81.
36. Goto H, et al. Expression of the nucleoprotein of rabies virus in Escherichia coli and mapping of antigenic sites. Archives of Virology 1995; 140: 1061-1074.
37. Dietzschold B, et al. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proceedings of the National Academy of Sciences USA 1987; 84: 9165-9169.
38. Lodmell DL, Smith JS, Esposito JJ. Cross-protection of mice against a global spectrum of rabies virus variants. Journal of Virology 1995; 69: 4957-5962.
39. Drings A, et al. Is there and advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine? Vaccine 1999; 17: 1549-1557.
40. Perry LL, Lodmell DL. Role of CD4+ and CD8+ T cells in murine resistance to street rabies virus. Journal of Virology 1991; 65 3429-3434.
41. Hooper DC, et al. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. Journal of Virology 1998; 72: 3711-3719.
42. Faber M, et al. Over-expression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune responses. Journal of Virology 2002; 76: 3374-3381.